Status:
NOT_YET_RECRUITING
Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD
Lead Sponsor:
University of Alberta
Collaborating Sponsors:
Novo Nordisk Canada Inc.
Conditions:
Chronic Kidney Disease in Type 2 Diabetes
Obesity & Overweight
Eligibility:
All Genders
18+ years
Brief Summary
Obesity is considered a global pandemic and is associated with various diseases and metabolic complications, such as type 2 diabetes mellitus, high blood pressure, cholesterol disorders, cancer, cardi...
Detailed Description
If participants agree to join the study, they will be asked to undergo a magnetic resonance imaging (MRI) scan to measure the fat around the heart, liver, and kidneys. During the abdominal MRI scan, t...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years of age.
- Patients diagnosed with T2DM (\>18 months) and CKD in stages G1, G2, G3a, G3b and G4; the CKD staging will be established according to the eGFR as per the KDIGO guidelines (G1: eGFR ≥90 ml/min/1.73m2; G2: 60-89 ml/min/1.73m2; G3a: 45-59 ml/min/1.73m2; G3b: 30-44 ml/ min/1.73m2; G4: 15-29 ml/ min/1.73m2).
- Patients with T2DM and CKD, with or without semaglutide treatment.
- Patients who voluntarily agree to participate and sign informed consent.
Exclusion
- Patients \<18 years of age.
- Pregnant, breastfeeding, or an intention of becoming pregnant or not using adequate contraceptive measures (including country-specific adequate measures, if any)
- Patients diagnosed with T2DM and CKD in stage G5 or stage G4 requiring dialysis as per KDIGO guidelines.
- Previous participation in this trial (screened or randomized)
- Patients diagnosed with neuropsychiatric diseases that prevent them from understanding the benefits/risks associated with the project or voluntarily choosing to participate.
- Known or suspected allergy to trial medication(s), excipients, or related products
- Contraindications to study medication(s), worded specifically as stated in the Product Monograph
- Refusal to participate or consent revocation.
Key Trial Info
Start Date :
December 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 15 2028
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT07187830
Start Date
December 15 2025
End Date
January 15 2028
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada, T6G 2B7